• Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.

      Cohen, K; Van Cutsem, G; Boulle, A; McIlleron, H; Goemaere, E; Smith, P J; Maartens, G; Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, South Africa. karen.cohen@uct.ac.za (Oxford Journals, 2008-02)
      BACKGROUND AND OBJECTIVES: Nevirapine-containing antiretroviral therapy (ART) and rifampicin-based antitubercular therapy are commonly co-administered in Africa, where nevirapine is often the only available non-nucleoside reverse transcriptase inhibitor. Rifampicin induces the metabolism of nevirapine, but the extent of the reduction in nevirapine concentrations has varied widely in previous studies. We describe the steady-state pharmacokinetics of nevirapine during and after antitubercular therapy in South African patients. METHODS: Sixteen patients receiving ART including standard doses of nevirapine were admitted twice for intensive pharmacokinetic sampling: during and after rifampicin-based antitubercular therapy. RESULTS: Geometric mean ratios for nevirapine pharmacokinetic parameters during versus after antitubercular therapy were 0.61 [90% confidence interval (CI) 0.49-0.79] for Cmax, 0.64 (90% CI 0.52-0.80) for area under the curve up to 12 h (AUC(0-12)) and 0.68 (90% CI 0.53-0.86) for Cmin. Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards. There was no correlation between rifampicin concentrations and the degree of nevirapine induction assessed by the proportional change in nevirapine concentrations between the two admissions. The ratio of nevirapine AUC(0-12) to the AUC(0-12) of its 12-hydroxy metabolite was significantly lower in the presence of antitubercular therapy, consistent with induced metabolism. CONCLUSIONS: Nevirapine concentrations were significantly decreased by concomitant rifampicin-based antitubercular therapy and a high proportion of patients had subtherapeutic plasma concentrations. Further study in African patients is required to determine the implications for treatment outcomes.
    • embCAB Sequence Variation Among Ethambutol-Resistant Mycobacterium Tuberculosis Isolates Without embB306 Mutation

      Plinke, C; Cox, H S; Zarkua, N; Karimovich, H A; Braker, K; Diel, R; Rüsch-Gerdes, S; Feuerriegel, S; Niemann, S; Molecular Mycobacteriology, Research Center Borstel, Germany; Macfarlane Burnet Institute for Medical Research and Public Health, Australia; Medecins Sans Frontieres, Uzbekistan; Ministry of Health, Uzbekistan; Medecins Sans Frontieres, Germany; Department of Pneumology, Medical School Hannover (MHH), Germany; National Reference Center for Mycobacteria, Research Center Borstel, Germany (2010-04-28)
      Mechanisms of resistance to ethambutol in Mycobacterium tuberculosis remain inadequately described. Although there is mounting evidence that mutations of codon 306 in embB play a key role, a significant number of phenotypically ethambutol-resistant strains do not carry mutations in this codon. Here, other mutations in the embCAB operon are suggested to be involved in resistance development.
    • Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship

      Bhatt, N B; Baudin, E; Meggi, B; da Silva, C; Barrail-Tran, A; Furlan, V; Grinsztejn, B; Bonnet, M; Taburet, A-M (Oxford University Press, 2014-09-18)
      We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial.